Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings

Figure 2 Treatment week 8 (A) and treatment week 8 to week 24 (B). A: These patients regardless of the treatment week 4 responses have a high possibility of SVR if they are HCVRNA negative (SVR > 87%) and are eligible for shortened therapy but if they are HCVRNA positive, then SVR rates are low, 35%-41.7%; B: After addition of boceprevir, with undetectable HCVRNA, these patients are eligible for shortened therapy (4 wk lead-in, 24 wk boceprevir +PR). However if they are HCVRNA positive then HCVRNA at weeks 10 and 12 are useful to guide therapy. Those who are HCVRNA ≥ 100 IU/mL at week 12 or have detectable HCVRNA at week 24 fulfill the stopping rules. ¹Not eligible for shortened therapy - should complete 32 wk BPR ± 12 wk PR or complete 44 wk BPR. HCV: Hepatitis C virus; PR: Pegylated interferon and ribavirin; SVR: Sustained virological response.